Pneuma Systems, a leading provider of infusion technology, has announced that their technology has been accepted into the FDA’s Safer Technologies Program (STeP). This program is highly selective and only accepts technologies that have the potential to significantly improve patient safety.
Pneuma Systems’ infusion technology is designed to improve the delivery of medications through innovative engineering and design. The technology has been recognized for its potential to reduce adverse events and improve patient outcomes.
The STeP program works to accelerate the development and regulatory review of medical devices that have the potential to make a significant impact on patient safety. By being accepted into this program, Pneuma Systems’ infusion technology is now eligible for expedited review and approval by the FDA.
This acceptance into the STeP program is a significant milestone for Pneuma Systems and highlights the potential impact of their infusion technology on patient safety. The company is committed to continuing to innovate and develop technologies that improve the delivery of medications to patients.
In a statement, Pneuma Systems expressed their excitement about being accepted into the STeP program and their commitment to advancing patient safety through their innovative infusion technology. They believe that this recognition from the FDA validates the importance of their work and the potential impact of their technology on patient care.
Overall, Pneuma Systems’ acceptance into the FDA’s STeP program is a testament to the potential of their infusion technology to improve patient safety and outcomes. This news is sure to have a positive impact on the company’s growth and development in the medical technology industry.
Source
Photo credit news.google.com